Abstract

ABSTRACTChlamydia trachomatis, an obligately intracellular bacterium, is the most prevalent cause of bacterial sexually transmitted infections (STIs) worldwide. Numbers of U.S. infections of the urogenital tract and rectum have increased annually. Because C. trachomatis is not easily cultured, comparative genomic studies are limited, restricting our understanding of strain diversity and emergence among populations globally. While Agilent SureSelectXT target enrichment RNA bait libraries have been developed for whole-genome enrichment and sequencing of C. trachomatis directly from clinical urine, vaginal, conjunctival, and rectal samples, public access to these libraries is not available. We therefore designed an RNA bait library (34,795 120-mer probes based on 85 genomes, versus 33,619 probes using 74 genomes in a previous one) to augment organism sequencing from clinical samples that can be shared with the scientific community, enabling comparison studies. We describe the library and limit of detection for genome copy input, and we present results of 100% efficiency and high-resolution determination of recombination and identical genomes within vaginal-rectal specimen pairs in women. This workflow provides a robust approach for discerning genomic diversity and advancing our understanding of the molecular epidemiology of contemporary C. trachomatis STIs across sample types, geographic populations, sexual networks, and outbreaks associated with proctitis/proctocolitis among women and men who have sex with men.IMPORTANCE Chlamydia trachomatis is an obligate intracellular bacterium that is not easily cultured, which limits our understanding of urogenital and rectal C. trachomatis transmission and impact on morbidity. To provide a publicly available workflow for whole-genome target enrichment and sequencing of C. trachomatis directly from clinical urine, vaginal, conjunctival, and rectal specimens, we developed and report on an RNA bait library to enrich the organism from clinical samples for sequencing. We demonstrate an increased efficiency in the percentage of reads mapping to C. trachomatis and identified recombinant and identical C. trachomatis genomes in paired vaginal-rectal samples from women. Our workflow provides a robust genomic epidemiologic approach to advance our understanding of C. trachomatis strains causing ocular, urogenital, and rectal infections and to explore geo-sexual networks, outbreaks of colorectal infections among women and men who have sex with men, and the role of these strains in morbidity.

Highlights

  • IMPORTANCE Chlamydia trachomatis is an obligate intracellular bacterium that is not cultured, which limits our understanding of urogenital and rectal C. trachomatis transmission and impact on morbidity

  • Total C. trachomatis genome copy input ranged from 265 to 7,854,406 copies, which is similar to the range for genome copies from clinical samples, with 1.33 to 99.28% of the quality-controlled reads binned as Chlamydia species, along with a mean mapping read depth to the C. trachomatis reference genome ranging from 0.57 to 562.67, respectively (Table 1; Fig. 1; see Fig. S1 in the supplemental material)

  • A SureSelectXT workflow with a 2.698 Mbp RNA bait library with 34,795 120-mer probes was developed from 85 GenBank C. trachomatis reference genomes encompassing all four lineages of C. trachomatis, compared to the previous RNA bait library developed from 74 GenBank C. trachomatis reference genomes with 33,619 120-mer probes [52]

Read more

Summary

Introduction

IMPORTANCE Chlamydia trachomatis is an obligate intracellular bacterium that is not cultured, which limits our understanding of urogenital and rectal C. trachomatis transmission and impact on morbidity. Our workflow provides a robust genomic epidemiologic approach to advance our understanding of C. trachomatis strains causing ocular, urogenital, and rectal infections and to explore geo-sexual networks, outbreaks of colorectal infections among women and men who have sex with men, and the role of these strains in morbidity. A 2016 meta-analysis of extragenital C. trachomatis and Neisseria gonorrhoeae infections in women, MSM, and men who have sex only with women (MSW) demonstrated median prevalences of 8.7%, 8.9%, and 7.7%, respectively, for rectal C. trachomatis, with infection often being asymptomatic [22]. In May 2019, the FDA cleared two diagnostic tests, the Aptima Combo 2 assay (Hologic, Inc.) and the Xpert CT/NG (Cepheid), for use with extragenital specimens in the detection of C. trachomatis and N. gonorrhoeae This recent diagnostic advancement will improve screening and surveillance capacity while offering an opportunity to better understand transmission of rectal C. trachomatis and its role in morbidity

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call